Ferroptosis Role in the Pathophysiology of Systemic Lupus Erythematosus
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: blood sample.
- Кому может быть актуально
- Состояния в реестре: Systemic Lupus Erythematosus. Базовые параметры: от 18 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Франция
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Обзор
The study aims at defining the role of ferroptosis s in the physiopathology of systemic lupus erythematosus (SLE). Ferroptosis (phenomenon of cellular death regulated by iron) is a metabolic pathway potentially implicated in SLE with potential for the discovery of new therapeutic strategies.
Подробное описание
Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting various organs. Regulatory T cells (Treg) and platelets play a crucial role in the pathogenesis of SLE by regulating immunity and promoting inflammation. Ferroptosis, an iron-regulated cell death process, is emerging as a key player in many diseases, including SLE.
The project, FERROLUP, aims to understand the role of ferroptosis in SLE and to explore the therapeutic potential of selenium compounds to modulate this process. Recent work has identified down-regulation of glutathione peroxidase 4 (GPx4) by immune complexes and interferon-alpha in neutrophils, leading to ferroptosis and worsening of SLE. In addition, data suggest the involvement of ferroptosis in lupus nephritis.
The Bordeaux team has developed selenium compounds, GPx4 mimics, capable of inhibiting ferroptosis in lupus neutrophils. These compounds have shown promising efficacy in mouse models and preliminary human studies in another inflammatory disease. The FERROLUP project aims to characterize the level of lipid peroxidation and GPx4 expression in SLE patients, and to test the impact of selenium compounds on the inhibition of ferroptosis induced by P-selectin, a molecule involved in Treg dysfunction.
Вмешательства
- Биопрепарат blood sample
30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
Первичные конечные точки
- Measurement of lipid peroxidation in regulatory T lymphocytes population in lupus subjects. [Срок оценки: At baseline (Day 0)]
Вторичные конечные точки (5)
- Measurement of lipid peroxidation in regulatory T lymphocytes population in lupus subjects and controls. [Срок оценки: At baseline (Day 0)]
- Measurement of lipid peroxidation in other immune cells (T and B lymphocyte populations) in lupus subjects and controls [Срок оценки: At baseline (Day 0)]
- GPX4 expression in lupus subjects and controls. [Срок оценки: At baseline (Day 0)]
- Correlation between ferroptosis markers and the level of activity in B lymphocyte populations [Срок оценки: At baseline (Day 0)]
- In-vitro effect of BXT on different T lymphocytes population in the presence of P-selectin in sera of lupus subjects and controls [Срок оценки: At baseline (Day 0)]
Критерии участия
Критерии включения
- age ≥ 18 years;
- diagnosis of systemic lupus erythematosus;
- being affiliated to health insurance, willing to participate and to sign informed consent;
- control group : patients with a diagnosis of rheumatoid arthritis or an inflammatory bowel disease.
Критерии исключения
- pregnant or breastfeeding women;
- patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Распределение
- Нерандомизированное
- Модель
- Параллельные группы
- Маскирование
- Открытое
- Основная цель
- Другое
Центры проведения
Франция · 1 центр
- CHU de Bordeaux - service de rhumatologie — Bordeaux
Идентификаторы
NCT: NCT07260942 · CHUBX 2025/003 · 2025-A00880-49